October 17, 2023
Company Description: A multi-indication, radiosensitizing platform to increase the effectiveness of radiotherapy and immunotherapy.
CEO/Top Company Official
Lead Product in Development
KORTUC - a multi-indication, radiosensitizing platform to enhance the effectiveness of radiotherapy and immunotherapy. For Breast Cancer, we are in a Registraitional P2 study that began in 2020 and will finish in 2025E.
Development Phase of Primary Product
Number Of Unlicensed Products